Antiepileptic drug treatment in the developmentally disabled: Treatment considerations with the newer antiepileptic drugs

Epilepsy and Behavior

Volumn 3, Issue 6 II, 2002, Pages

  Rutecki, Paul A ^a   Gidal, Barry E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Antiepileptic drugs; Developmentally disabled; Felbamate; Gabapentin; Lamotrigine; Levetiracetam; Oxcarbazepine; Tiagabine; Topiramate; Zonisamide

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; NEW DRUG; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PSYCHOTROPIC AGENT; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANOREXIA; APLASTIC ANEMIA; ATAXIA; BEHAVIOR DISORDER; BINDING COMPETITION; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; DEVELOPMENTAL DISORDER; DISABLED PERSON; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FREQUENCY ANALYSIS; HEADACHE; HEMIPARESIS; HUMAN; HYPONATREMIA; INSOMNIA; LIVER FAILURE; LIVER METABOLISM; MENTAL DEFICIENCY; NEPHROLITHIASIS; PROTEIN BINDING; QUALITY OF LIFE; RASH; REVIEW; SALIVATION; SEDATION; SIDE EFFECT; SLURRED SPEECH; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VERTIGO;

EID: 0042886035     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1525-5050(02)00539-5     Document Type: Review

References (44)

1. Airaksinen EM, Matilainen R, Mononen T, et al. A population-based study on epilepsy in mentally retarded children. Epilepsia 2000;41:1214-20.
2. Alvarez N, Besag F, Iivanainen M. Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res 1998;42(Suppl 1):1-15.
3. Bowley C, Kerr M. Epilepsy and intellectual disability. J Intellect Disabil Res 2000;44(pt. 5):529-43.
4. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29: 233-49.
5. Bhaumik S, Branford D, Duggirala C, Ismail IA. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure 1997;6:127-33.
6. Crawford P, Brown S, Kerr M. A randomized, open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. Seizure 2001;10:107-15.
7. Mikati MA, Choueri R, Khurana DS, Riviello J, Helmers S, Holmes G. Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. J Intellect Disabil Res 1998;42(Suppl 1):57-62.
8. Lee DO, Steingard RJ, Cesena M, Helmers SL, Riviello JJ, Mikati MA. Behavioral side effects of gabapentin in children. Epilepsia 1996;37:87-90.
9. Tallian KB, Nahata MC, Lo W, Tsao CY. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996;37:501-2.
10. Ritter FJ, Leppik IE, Dreifuss FE, et al. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328:29-33.
11. Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res 2000;42:23-31.
12. Dulac O, Kaminska A. Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J Child Neurol 1997;12(Suppl 1): S23-8.
13. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807-12.
14. Uvebrant P, Bauziene R. Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:284-9.
15. King JA, Knight JE, Oommen KJ. Efficacy of lamotrigine in the developmentally disable (abstract). Epilepsia 1996;37:162.
16. Gidal BE, Walker JK, Lott RS, et al. Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation. Seizure 2000;9:131-6.
17. Coppola G, Pascotto A. Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. Brain Dev 1997;19:398-402.
18. Sorensen T, Mai J, Friis ML. Long-term follow-up on lamotrigine in treatment of epilepsy in the mentally retarded (abstract). Epilepsia 1998;39:130.
19. McKee JR, Sunder TR, Vuong A, et al. Lamotrigine adjunctive therapy in patients with mental retardation and refractory epilepsy in institutional and home settings (abstract). Epilepsia 2001;42:183.
20. Maganti R, Gidal BE, Shaw R, Rutecki P. Concomitant use of divalproex sodium and lamotrigine in developmentally disabled patients with epilepsy: a retrospective evaluation of efficacy and tolerability. Epilepsy Behav; 3:275-9.
21. Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998;39:280-2.
22. Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-7.
23. Besag F, Cox A, Berry D. Atypical presentation of carbamazepine toxicity from pharmacokinetic interaction with lamotrigine in people with learning disability (abstract). Epilepsia 1999; 40:254.
24. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345:476-9.
25. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. UK Lamotrigine Elderly Study Group. Epilepsy Res 1999;37:81-7.
26. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.
27. Messenheimer JA, Tennis P. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs commonly used in Germany: adult and pediatric incidence estimates from registry and prescription data. Neurology 2002;58(Suppl 3):A175-6.
28. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999;33:1037-42.
29. Messenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf 2000;22:303-12.
30. Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure 2000;9:282-6.
31. Gustafson MC, Ritter F, Frost MD, et al. Clinical experience with levetiracetam treating refractory, symptomatic seizures in children (abstract). Epilepsia 2001;42:55.
32. Bourgeois BF, Holder DL, Valencia I, et al. Open-label assessment of levetiracetam efficacy and adverse effects in a pediatric population. Epilepsia 2001;42:53-4.
33. Wheless JW, Ng YT. Levetiracetam in refractory pediatric epilepsy. J Child Neurol 2002;17:413-5.
34. Welty TE, Gidal BE, Ficker DM, Privitera MD. Levetiracetam: a different approach to the pharmacotherapy of epilepsy. Ann Pharmacother 2002;36:296-304.
35. Gaily E, Granstrom ML, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intellect Disabil Res 1998;42:41-5.
36. Schachter SC. A review of the antiepileptic drug tiagabine. Clin Neuropharmacol 1999;22:312-7.
37. Pellock JM. Tiagabine (gabitril) experience in children. Epilepsia 2001;42(Suppl 3):49-51.
38. Holden KR, Titus MO. The effect of tiagabine on spasticity in children with intractable epilepsy: a pilot study. Pediatr Neurol 1999;21:728-30.
39. Eckardt KM, Steinhoff BJ. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia 1998;39:671-4.
40. Fitzek S, Hegemann S, Sauner D, Bonsch D, Fitzek C. Drug-induced nonconvulsive status epilepticus with low dose of tiagabine. Epileptic Disord 2001;3:147-50.
41. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52: 1882-7.
42. Singh BK, White-Scott S. Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure 2002;11:47-50.
43. Iinuma K, Minami T, Cho K, Kajii N, Tachi N. Long-term effects of zonisamide in the treatment of epilepsy in children with intellectual disability. J Intellect Disabil Res 1998;42(Suppl 1): 68-73.
44. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998;29:147-54.